Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin Apotheke
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in: memo - Magazine of European Medical Oncology 1/2023

30.11.2022 | short review

Total neoadjuvant therapy in rectal cancer

verfasst von: Dr. Gudrun Piringer, MSc, Prim. Univ.-Doz. Dr. Alexander De Vries

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Summary

Total neoadjuvant therapy is a novel approach for locally advanced rectal cancer. The optimal treatment sequence is, however, a matter of debate and until now, no overall survival benefit has been reported. This review is a critical, objective summary viewed from different perspectives of the available literature of previous milestones that have been achieved in the treatment of locally advanced rectal cancer, of current recommendations, and of future perspectives.
Vorheriger Artikel News on Peripheral T-cell lymphoma
Nächster Artikel Surgical management of liver metastasis from colorectal cancer
Literatur
1.
Enker WE, Laffer UT, Block GE. Enhanced survival of patients with colon and rectal cancer is based upon wide anatomic resection. Ann Surg. 1979;190(3):350–60.PubMedPubMedCentralCrossRef
2.
Pollett WG, Nicholls RJ. The relationship between the extent of distal clearance and survival and local recurrence rates after curative anterior resection for carcinoma of the rectum. Ann Surg. 1983;198(2):159–63.PubMedPubMedCentralCrossRef
3.
Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don’t know. JAMA. 1988;259(24):3571–8.PubMedCrossRef
4.
5.
Cedermark B, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336(14):980–7.PubMedCrossRef
6.
Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.PubMedCrossRef
7.
Kapiteijn E, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.PubMedCrossRef
8.
Brown G, et al. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? Br J Cancer. 2004;91(1):23–9.PubMedPubMedCentralCrossRef
9.
10.
Beets-Tan RG, Beets GL. Local staging of rectal cancer: a review of imaging. J Magn Reson Imaging. 2011;33(5):1012–9.PubMedCrossRef
11.
Beets-Tan RG. MRI in rectal cancer: the T stage and circumferential resection margin. Colorectal Dis. 2003;5(5):392–5.PubMedCrossRef
12.
Maughan NJ, Quirke P. Modern management of colorectal cancer—a pathologist’s view. Scand J Surg. 2003;92(1):11–9.PubMedCrossRef
13.
Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26(2):303–12.PubMedCrossRef
14.
Nagtegaal ID, et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol. 2005;23(36):9257–64.PubMedCrossRef
15.
Quirke P. Training and quality assurance for rectal cancer: 20 years of data is enough. Lancet Oncol. 2003;4(11):695–702.PubMedCrossRef
16.
van den Broek CB, et al. Differences in pre-operative treatment for rectal cancer between Norway, Sweden, Denmark, Belgium and the Netherlands. Eur J Surg Oncol. 2014;40(12):1789–96.PubMedCrossRef
17.
van Gijn W, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82.PubMedCrossRef
18.
Breugom AJ, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(2):200–7.PubMedCrossRef
19.
Bosset J‑F, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184–90.PubMedCrossRef
20.
Schmoll HJ, et al. Pre- and postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. J Clin Oncol. 2021;39(1):17–29.PubMedCrossRef
21.
Rödel C, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13(7):679–87.PubMedCrossRef
22.
Kim TW, et al. Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up. Int J Radiat Oncol Biol Phys. 2011;81(4):1025–31.PubMedCrossRef
23.
Marijnen CA, et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55(5):1311–20.PubMedCrossRef
24.
Strassburg J, et al. MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study. Ann Surg Oncol. 2011;18(10):2790–9.PubMedCrossRef
25.
Junginger T, et al. Rectal carcinoma: is too much neoadjuvant therapy performed? Proposals for a more selective MRI based indication. Zentralbl Chir. 2006;131(4):275–84.PubMedCrossRef
26.
Kreis ME, et al. Use of preoperative magnetic resonance imaging to select patients with rectal cancer for neoadjuvant chemoradiation—interim analysis of the German OCUM trial (NCT01325649). J Gastrointest Surg. 2016;20(1):25–32. discussion 32–33.PubMedCrossRef
27.
Ruppert R, et al. Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM rectal cancer trial. Br J Surg. 2018;105(11):1519–29.PubMedCrossRef
28.
Ruppert R, et al. Avoidance of overtreatment of rectal cancer by selective chemoradiotherapy: results of the optimized surgery and MRI-based multimodal therapy trial. J Am Coll Surg. 2020;231(4):413–425.e2.PubMedCrossRef
29.
Maas M, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44.PubMedCrossRef
30.
Petrelli F, et al. Pathologic complete response and disease-free survival are not surrogate endpoints for 5‑year survival in rectal cancer: an analysis of 22 randomized trials. J Gastrointest Oncol. 2017;8(1):39–48.PubMedPubMedCentralCrossRef
31.
Sargent D, et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X‑ACT, PETACC‑3, C‑06, C‑07 and C89803. Eur J Cancer. 2011;47(7):990–6.PubMedPubMedCentralCrossRef
32.
Merkel S, et al. Time to locoregional recurrence after curative resection of rectal carcinoma is prolonged after neoadjuvant treatment: a systematic review and meta-analysis. Colorectal Dis. 2011;13(2):123–31.PubMedCrossRef
33.
34.
Aschele C, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773–80.PubMedCrossRef
35.
Deng HY, et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer. Eur J Cardiothorac Surg. 2017;51(3):421–31.PubMed
36.
Wiśniowska K, et al. Does the addition of oxaliplatin to preoperative chemoradiation benefit cT4 or fixed cT3 rectal cancer treatment? A subgroup analysis from a prospective study. Eur J Surg Oncol. 2016;42(12):1859–65.PubMedCrossRef
37.
Gerard JP, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638–44.PubMedCrossRef
38.
Rödel C, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89.PubMedCrossRef
39.
Bittner R, et al. Report on the workshop “workflow rectal cancer II” in Burghausen. Zentralbl Chir. 2007;132(2):95–8.PubMedCrossRef
40.
Buhr HJ, et al. Clinical pathway (workflow) for diagnostic, therapy and follow-up in patients with rectal cancer. Zentralbl Chir. 2006;131(4):285–97.PubMedCrossRef
41.
Roxburgh CSD, et al. Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short-term outcomes. Colorectal Dis. 2019;21(10):1140–50.PubMedPubMedCentralCrossRef
42.
Conroy T, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702–15.PubMedCrossRef
43.
Bahadoer RR, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42.PubMedCrossRef
44.
Garcia-Aguilar J, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546–56.PubMedCrossRef
45.
Fokas E, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol. 2022;8(1):e215445.PubMedCrossRef
46.
47.
Benson AB, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(7):874–901.PubMedCrossRef
48.
49.
Smith JJ, et al. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3‑year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015;15:767.PubMedPubMedCentralCrossRef
50.
Ludmir EB, et al. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer. 2017;123(9):1497–506.PubMedCrossRef
51.
Wang X, et al. Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: a phase 2 trial. Radiother Oncol. 2018;129(2):300–5.PubMedCrossRef
52.
Riesco-Martinez MC, et al. Impact of total neoadjuvant therapy vs. standard chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis of randomized trials. Cancers (Basel). 2020;12(12):3655.PubMedCrossRef
53.
Liu S, et al. Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Oncologist. 2021;26(9):e1555–e66.PubMedPubMedCentralCrossRef
54.
Valadão M, et al. Do we have to treat all T3 rectal cancer the same way? Clin Colorectal Cancer. 2020;19(4):231–5.PubMedCrossRef
55.
Lee JB, et al. Role of preoperative chemoradiotherapy in clinical stage II/III rectal cancer patients undergoing total mesorectal excision: a retrospective propensity score analysis. Front Oncol. 2020;10:609313.PubMedCrossRef
56.
Bujko K, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27(5):834–42.PubMedCrossRef
57.
Ciseł B, et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30(8):1298–303.PubMedCrossRef
58.
Benson AB, et al. NCCN guidelines insights: rectal cancer, version 6.2020. J Natl Compr Canc Netw. 2020;18(7):806–15.PubMedCrossRef
59.
Harrison JD, et al. Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. Arch Surg. 2008;143(4):389–94.PubMedCrossRef
60.
Breugom AJ, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26(4):696–701.PubMedCrossRef
61.
Goodman KA. Definitive chemoradiotherapy (“watch-and-wait” approach). Semin Radiat Oncol. 2016;26(3):205–10.PubMedCrossRef
62.
Lopez-Campos F, et al. Watch and wait approach in rectal cancer: current controversies and future directions. World J Gastroenterol. 2020;26(29):4218–39.PubMedPubMedCentralCrossRef
63.
Xu Q, et al. MRI evaluation of complete response of locally advanced rectal cancer after neoadjuvant therapy: current status and future trends. Cancer Manag Res. 2021;13:4317–28.PubMedPubMedCentralCrossRef
64.
Dattani M, et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg. 2018;268(6):955–67.PubMedCrossRef
65.
Habr-Gama A, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7. discussion 717–8.PubMedPubMedCentralCrossRef
66.
Habr-Gama A, et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53(12):1692–8.PubMedCrossRef
67.
Glynne-Jones R, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22–iv40.PubMedCrossRef
68.
Yu M, et al. Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses. Int J Colorectal Dis. 2022;37(4):855–68.PubMedCrossRef
69.
Petrelli F, et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. 2016;263(3):458–64.PubMedCrossRef
70.
Deidda S, et al. Association of delayed surgery with oncologic long-term outcomes in patients with locally advanced rectal cancer not responding to preoperative Chemoradiation. JAMA Surg. 2021;156(12):1141–9.PubMedPubMedCentralCrossRef
71.
Dizdarevic E, Hansen TF, Jakobsen A. The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal. Cancers (Basel). 2022;14(9):2252.PubMedCrossRef
72.
Murahashi S, et al. Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. Br J Cancer. 2020;123(5):803–10.PubMedPubMedCentralCrossRef
73.
Vidal J, et al. Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD 1402 trial. Clin Cancer Res. 2021;27(10):2890–8.PubMedCrossRef
74.
Kotaka M, et al. Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. J Clin Oncol. 2022;40(4_suppl):9.CrossRef
75.
Bach SP, et al. STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer? J Clin Oncol. 2022;40(16_suppl):3502–3502.CrossRef
76.
Hearn N, et al. Neoadjuvant radiotherapy dose escalation in locally advanced rectal cancer: a systematic review and meta-analysis of modern treatment approaches and outcomes. Clin Oncol. 2021;33(1):e1–e14.CrossRef
77.
78.
André T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18.PubMedCrossRef
79.
Overmann MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9.CrossRef
80.
Cercek A, et al. PD‑1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Eng J Med. 2022;386:2363–76.CrossRef
Metadaten
Titel
Total neoadjuvant therapy in rectal cancer
verfasst von
Dr. Gudrun Piringer, MSc
Prim. Univ.-Doz. Dr. Alexander De Vries
Publikationsdatum
30.11.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00854-1

Weitere Artikel der Ausgabe 1/2023

memo - Magazine of European Medical Oncology 1/2023 Zur Ausgabe

short review

Vaccination against SARS-CoV-2 in adults with a diagnosis of cancer: a short review

short review

Radiotherapy update: current role of radiotherapy in the treatment of lymphomas

short review

Surgical management of liver metastasis from colorectal cancer

editorial

Radiooncology and nuclear medicine

position paper

Barriers to patient access of CAR T cell therapies in Austria

short review

Dual immune checkpoint blockade in gastroesophageal tumors: never say never